+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Multicenter evaluation of the ACS RX MULTI-LINK DUET coronary stent system in native de novo coronary lesions The DUET study



Multicenter evaluation of the ACS RX MULTI-LINK DUET coronary stent system in native de novo coronary lesions The DUET study



European Heart Journal 20(ABSTR SUPPL ): 157




(PDF emailed within 1 workday: $29.90)

Accession: 035349804

Download citation: RISBibTeXText


Related references

Clinical and angiographic results with the ACS MULTI-LINK DUET trade mark Coronary Stent System - the DUET Study. International Journal of Cardiovascular Interventions 3(2): 97-104, 2002

Acute and 6-month clinical and angiographic outcome after implantation of the ACS Duet stent for single-vessel coronary artery disease: final results of the European and US ACS Multi-link Duet Registry. Catheterization and Cardiovascular Interventions 54(1): 25-33, 2001

Procedural and late outcomes following MULTI-LINK DUET coronary stent deployment. American Journal of Cardiology 84(12): 1385-1390, Dec 15, 1999

Procedural and late outcomes following Multi-Link DUET coronary stent deployment Final report for the US Registry. Journal of the American College of Cardiology 33(2 SUPPL A): 95A, 1999

A randomized trial comparing the hand-mounted JoStent with the premounted Multi-Link Duet stent in patients with coronary artery disease. Catheterization and Cardiovascular Interventions 54(4): 414-419, 2001

Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). Jacc. Cardiovascular Interventions 2(12): 1208-1218, 2010

Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials. Jacc. Cardiovascular Interventions 3(12): 1220-1228, 2011

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesion. Jacc. Cardiovascular Interventions 3(12): 1229-1239, 2011

The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) trial. Jacc. Cardiovascular Interventions 2(3): 205-214, 2010

3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). Jacc. Cardiovascular Interventions 2(12): 1190-1198, 2010

A randomized trial comparatively assessing 2 second-generation coronary stents MULTI-LINK duet and JOSTENT. European Heart Journal 21(Abstract Supplement): 263, August-September, 2000

First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial. Jacc. Cardiovascular Interventions 2(3): 197-204, 2010

Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. American Heart Journal 166(6): 1035-1042, 2014

The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions. Jacc. Cardiovascular Interventions 4(2): 168-175, 2011

A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. Journal of the American College of Cardiology 57(16): 1700-1708, 2011